Replies to post #42993 on Biotech Values

[biophud]

Question for the board. Assuming regulatory sucess, which MS pts will BIIB/PDLI target with Daclizumab?

With 3 products for MS (Interferon, Tysabri, Daclizumab) is there a risk that BIIB will cannabilize sales of the other two drugs? Comments appreciated.

biophud